Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV , a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The four-in-one test is designed for use on any of Cepheid’s over 26,000 GeneXpert® Systems placed worldwide, with results delivered in approximately 36 minutes.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test | 4 | 905 | April 4, 2020 | |
| Laboratories can obtain accurate and rapid results with Cepheid’s Xpert® Xpress SARS-CoV-2 Test: Webinar | 0 | 375 | April 14, 2020 | |
| Video: Leveraging GeneXpert for Tuberculosis and SARS-CoV-2 Testing | 0 | 624 | April 22, 2020 | |
| Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV) | 0 | 445 | April 1, 2020 | |
| FDA grants first emergency use ok for at-home COVID-19 test | 0 | 364 | November 19, 2020 |